Lensar (LNSR) Cash from Financing Activities (2019 - 2026)
Lensar's (LNSR) quarterly Cash from Financing Activities came in at -$209000.0 in Q1 2026, down 102.16% year-on-year from $9.7 million in Q1 2025, and down 144.09% on a QoQ basis from $474000.0 in Q4 2025.
Lensar (LNSR) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Lensar (LNSR) has 8 years of Cash from Financing Activities data on file, last reported at -$209000.0 in Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 102.16% year-over-year to -$209000.0 in Q1 2026; TTM through Mar 2026 was $358000.0, a 96.38% decrease from a year earlier, with the FY2025 full-year figure at $10.3 million, up 13051.28% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$209000.0, down from $474000.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for LNSR reached as high as $9.7 million in Q1 2025 and fell as low as -$1.2 million in Q3 2022.
- Historically, Cash from Financing Activities has averaged $755333.3 across 5 years, with a median of $111000.0 in 2024.
- Across the five-year window, Cash from Financing Activities soared 7554.62% in 2025 and sank 102.16% in 2026, its largest moves.
- Year by year, Cash from Financing Activities stood at $196000.0 in 2022, then fell by 25.51% to $146000.0 in 2023, then rose by 17.81% to $172000.0 in 2024, then surged by 175.58% to $474000.0 in 2025, then tumbled by 144.09% to -$209000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$209000.0 in Q1 2026, $474000.0 in Q4 2025, and $93000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Lensar | 70.05 Mn | 72.73 Mn | 6.38 Mn | -209,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -209,000.00 |
| Mar 31, 2026 | -209,000.00 |
| Dec 31, 2025 | 474,000.00 |
| Dec 31, 2025 | 474,000.00 |
| Jun 30, 2025 | 93,000.00 |
| Jun 30, 2025 | 93,000.00 |
| Mar 31, 2025 | 9.69 Mn |
| Mar 31, 2025 | 9.69 Mn |
| Dec 31, 2024 | 172,000.00 |
| Dec 31, 2024 | 172,000.00 |
| Sep 30, 2024 | -93,000.00 |
| Sep 30, 2024 | -93,000.00 |
| Jun 30, 2024 | 129,000.00 |
| Jun 30, 2024 | 129,000.00 |
| Mar 31, 2024 | -130,000.00 |
| Mar 31, 2024 | -130,000.00 |
| Dec 31, 2023 | 146,000.00 |
| Dec 31, 2023 | 146,000.00 |
| Sep 30, 2023 | -205,000.00 |
| Sep 30, 2023 | -205,000.00 |